TGen's platform.org social media analysis has advanced to the final round for a global social-success recognition

TGen's platform.org social media analysis has advanced to the final round for a global social-success recognition

In a significant stride towards understanding and combating Alzheimer's disease, the Translational Genomics Research Institute (TGen) in Phoenix, Arizona, has launched an innovative online research project called Our Platform. This initiative aims to engage a massive population of participants, with a goal of reaching 1 million people, to better comprehend the disease's genetics and progression.

TGen, a finalist for the CLASSY Awards - the largest social impact celebration recognising champions of social progress - is spearheading this ambitious project. The awards ceremony will take place on May 3, 2014, at the Marriott Marquis in San Diego.

Dr. Huentelman, the lead researcher on the project, encourages the public to participate in the 10-minute, anonymous test available on TGen's website. The platform.org study plans to utilise statistical analysis and genetic testing to identify factors associated with brain performance. Already, nearly 28,000 volunteers have taken the test, with a goal of gathering results from as many as 1 million participants.

The importance of such large-scale online participation in Alzheimer's research is underscored by initiatives like MindCrowd, which has successfully engaged diverse populations in cognitive aging studies. Such projects emphasise the importance of scalable online participation to improve representation and research outcomes.

Moreover, collaborations such as that between Tempus AI and Northwestern University's Abrams Research Center demonstrate how advanced AI platforms are used to analyse genomic data to drive Alzheimer's research forward. This aligns with the type of aims TGen’s Our Platform likely shares - leveraging big data and broad participation to uncover actionable insights for disease understanding and treatment.

Alzheimer's disease is a socioeconomic epidemic, impacting more than 5 million Americans, being the 6th leading cause of death in the U.S., and costing the nation over $200 billion annually to treat. TGen's focus is on helping patients with cancer, neurological disorders, and diabetes through cutting-edge translational research.

TGen physicians and scientists work to unravel the genetic components of both common and rare complex diseases in adults and children. The institute collaborates with scientists and medical professionals worldwide to contribute to patient care through the efficiency and effectiveness of the translational process.

For more information about TGen and the Our Platform project, visit www.tgen.org. The press contact for TGen is Steve Yozwiak, TGen Senior Science Writer, who can be reached at 602-343-8704 or [email protected].

The CLASSY Awards, the largest social impact awards ceremony in the United States, taking place from May 2-3, 2014, in San Diego, will acknowledge the winners in various categories, including the winner for the TGen platform.org study. The CLASSY Leadership Council on Health will determine the winners.

This online research project by TGen represents a significant step in the broader movement towards data-driven, online research platforms designed to accelerate breakthroughs in Alzheimer's disease by harnessing vast participant cohorts and cutting-edge technology. The ultimate goal is to develop a better-informed cure for Alzheimer's, and with the public's support, TGen is one step closer to achieving this milestone.

1. The Translational Genomics Research Institute (TGen) is focusing on neurogenomics, using science to combat Alzheimer's disease, a socioeconomic epidemic that affects more than 5 million Americans.
2. TGen's online research project, Our Platform, is designed to gather results from as many as 1 million participants for a better understanding of Alzheimer's disease genetics and progression.
3. Collaborations, such as Tempus AI and Northwestern University's Abrams Research Center, are utilizing advanced AI platforms in analyzing genomic data for mental health issues like Alzheimer's, aligning with TGen's approach in its Our Platform project.
4. To support health and wellness, especially in managing aging-related neurodegenerative diseases like Alzheimer's, CBD products haven't been completely researched for their neurological disorder effects, making it a potential avenue for future studies.

Read also: